(Registrieren)

EMEA Committee Recommends Orphan Medicinal Product Designation for ISA247 for the Treatment of Uveitis

Geschrieben am 01-08-2007

Edmonton, Canada (ots/PRNewswire) - Isotechnika Inc. (TSX:ISA)
announced today that the European Agency for the Evaluation of
Medicinal Products (EMEA) committee for Orphan Medicinal Products has
adopted a positive opinion on orphan medicinal product designation
for ISA247 for the treatment of chronic, non-infectious uveitis. The
EMEA will now forward the opinion to the European Commission. The
Decision will be adopted by the Commission within 30 days of its
receipt. Orphan Drug designation provides a variety of incentives,
including market exclusivity for up to 10 years following approval,
fee reductions and free Scientific Advice.

Isotechnika's partner, Lux Biosciences, began enrolling patients
in pivotal clinical trials for ISA247 earlier this year. The company
is conducting three controlled, double-masked studies aimed at
supporting the approval of that product as a treatment for uveitis,
collectively designated the LUMINATE program. The LUMINATE program
represents the largest and most comprehensive clinical program ever
undertaken in the field of uveitis.

About ISA247

Isotechnika's lead drug, ISA247, is a calcineurin inhibitor to
which Lux Biosciences has an exclusive worldwide license for
ophthalmic indications. ISA247 is currently being investigating in a
combined European/Canadian Phase 3 psoriasis trial and in a North
American Phase 2b kidney transplant trial. In addition to uveitis,
Lux Biosciences plans to develop this molecule in other ophthalmic
indications, including dry eye syndrome and age-related macular
degeneration. Lux Biosciences was previously granted orphan drug
status for ISA247 by the FDA in USA.

About Isotechnika

Edmonton-based Isotechnika Inc. is an international
biopharmaceutical company focused on the discovery and development of
novel immunosuppressive therapeutics that are designed to offer
advantages over other currently available treatments while offering
therapeutic choices to clinicians. Isotechnika looks to become the
market leader of drug therapies for indications such as
transplantation of solid organs (with Hoffman La Roche) and treatment
of autoimmune disorders such as uveitis (with Lux Biosciences) and
psoriasis.

There is a significant unmet medical need in the treatment of both
solid organ transplantation and autoimmune disease. It is estimated
that the market potential exceeds US$2 billion annually in sales for
calcineurin inhibitors such as ISA247.

Isotechnika's lead drug, ISA247, has successfully completed a
Phase 3 Canadian trial for the treatment of moderate to severe
psoriasis. ISA247 is currently being investigated in a Phase 3
European/Canadian psoriasis trial and a Phase 2b North American trial
for the prevention of kidney graft rejection subsequent to
transplantation.

Isotechnika Inc. is a publicly traded company on the Toronto Stock
Exchange under the symbol "ISA". More information on Isotechnika can
be found at www.isotechnika.com.

Partnerships with Isotechnika Inc.

Isotechnika Inc. signed a collaboration agreement with Hoffman La
Roche on April 9, 2002, which licensed the worldwide rights to
develop and commercialize ISA247 for all transplant indications.

On September 30, 2005, Isotechnika Inc. entered into an exclusive
worldwide licensing agreement with Atrium Medical Corporation for the
use of ISA247 and TAFA93 specifically with drug eluting devices for
the non-systemic treatment of vascular, cardiovascular, target vessel
and tissue disorders.

Isotechnika Inc. and Cellgate Inc. signed an option agreement on
April 25, 2006, granting Isotechnika the option to obtain an
exclusive license to develop and commercialize conjugates consisting
of Cellgate's patented transporter technology for the topical
delivery of ISA247 in patients suffering from mild to moderate
psoriasis.

On May 25, 2006, Isotechnika Inc. signed an agreement with Lux
Biosciences, Inc. of Jersey City, New Jersey granting Lux Biosciences
worldwide rights to develop and commercialize Isotechnika's lead
drug, ISA247 for the treatment and prophylaxis of all ophthalmic
diseases.

Forward-Looking Statements

This press release may contain forward-looking statements. Forward
looking statements, including the Company's belief as to the
potential of its products, the Company's expectations regarding the
issuance of additional patents and the Company's ability to protect
its intellectual property, involve known and unknown risks and
uncertainties, which could cause the Company's actual results to
differ materially from those in the forward looking statements. Such
risks and uncertainties include, among others, the availability of
funds and resources to pursue research and development projects, the
ability to economically manufacture its products, the potential of
its products, the success and timely completion of clinical studies
and trials, the Company's ability to successfully commercialize its
products, the ability of the Company to defend its patents from
infringement by third parties, and the risk that the Company's
patents may be subsequently shown to be invalid or infringe the
patents of others. Investors should consult the Company's quarterly
and annual filings with the Canadian commissions for additional
information on risks and uncertainties relating to the forward-
looking statements. Investors are cautioned against placing undue
reliance on forward-looking statements.

ots Originaltext: Isotechnika Inc.
Im Internet recherchierbar: http://www.presseportal.de

Contact:
For further information: Dr. Randall Yatscoff, President & CEO,
Isotechnika Inc., Phone: +1-780-487-1600-(247), Fax: +1-780-484-4105,
ryatscoff@isotechnika.com; Stephanie Gillis-Paulgaard, Director,
Corporate Communications, Isotechnika Inc., Phone: +1-780-909-4661,
Fax: +1-780-484-4105, sgillis-paulgaard@isotechnika.com; Lux
Biosciences, Inc., Ulrich Grau, Ph.D., Phone: +1-201-946-0221,
ulrich.grau@luxbio.com


Kontaktinformationen:

Leider liegen uns zu diesem Artikel keine separaten Kontaktinformationen gespeichert vor.
Am Ende der Pressemitteilung finden Sie meist die Kontaktdaten des Verfassers.

Neu! Bewerten Sie unsere Artikel in der rechten Navigationsleiste und finden
Sie außerdem den meist aufgerufenen Artikel in dieser Rubrik.

Sie suche nach weiteren Pressenachrichten?
Mehr zu diesem Thema finden Sie auf folgender Übersichtsseite. Desweiteren finden Sie dort auch Nachrichten aus anderen Genres.

http://www.bankkaufmann.com/topics.html

Weitere Informationen erhalten Sie per E-Mail unter der Adresse: info@bankkaufmann.com.

@-symbol Internet Media UG (haftungsbeschränkt)
Schulstr. 18
D-91245 Simmelsdorf

E-Mail: media(at)at-symbol.de

84787

weitere Artikel:
  • AerCap Holdings N.V. plant Veröffentlichung seiner Finanzergebnisse für das zweite Quartal 2007 am 7. August 2007 Amsterdam, Niederlande (ots/PRNewswire) - AerCap Holdings N.V. ("AerCap," NYSE: AER) gab heute bekannt, dass das Unternehmen vor hat, am Dienstag, den 7. August 2007 vor Marktöffnung eine Pressemitteilung über sein Finanzergebnis für das zweite Quartal 2007 zu veröffentlichen. Eine Kopie der Pressemitteilung wird im Bereich "Investor Relations" auf der AerCap Website unter http://www.aercap.com publiziert. Das Unternehmen wird am Dienstag, den 7. August 2007, um 9:30 Uhr (Eastern Time) eine Telefonkonferenz abhalten, um die Ergebnisse mehr...

  • Börsen-Zeitung: Reinigendes Gewitter, Kommentar zur Krisenstimmung an den Märkten von Claus Döring Frankfurt (ots) - Ein 31% höheres Quartalsergebnis bei der Deutschen Bank, 28% mehr bei Conti, wachsende Gewinne und positive Ausblicke bei BASF und anderen Blue Chips, die jetzt ihre Zahlen präsentieren: An den Märkten erschien dies wie die Botschaft aus der fernen heilen Welt von gestern. Die Welt von heute und morgen sieht anders aus: im Tagesrhythmus kollabierende Hedgefonds und Immobilienfinanzierer, deren Geschäftsrisiko rund um die Welt weit in die Tiefen bisher unverdächtiger Portfolios hineindiversifiziert ist. Wer die US-Immobilienkrise mehr...

  • MDS Pharma Services Expands Development & Regulatory Services in Europe King Of Prussia, Pennsylvania (ots/PRNewswire) - MDS Pharma Services, a leading provider of innovative drug discovery and development solutions, announced today the expansion of its Development & Regulatory Services (DRS) business in Europe. MDS Pharma Services will now offer full-service DRS consulting services to support development of new drugs and biopharmaceutical products for clients in Europe. The MDS Pharma Services' European DRS organization will also be fully integrated with consultants in the United States and Canada to provide mehr...

  • LVZ: Im Bann der Schlange Leipzig (ots) - Von Thomas Strohm Die Deutsche Bank meldet das beste zweite Quartal ihrer Geschichte, der weltgrößte Chemiekonzern BASF legt glänzende Zahlen vor, auch BMW, Metro, Henkel und Continental verkünden mehr oder weniger Erfolge. Und trotz guter Nachrichten von gleich sechs Dax-Konzernen bricht der Leitindex zum Handelsstart ein. Die Angst geht um auf dem Parkett. Angst vor der Krise auf dem US-Immobilienmarkt, die inzwischen auch über den großen Teich herübergeschwappt ist und der IKB-Bank einen solchen Schlag verpasst hat, mehr...

  • TrackWise Software wurde von Bayer HealthCare AG für das globale Audit-Management in den Bereichen GCP und GLP ausgewählt Holmdel, New Jersey (ots/PRNewswire) - Sparta Systems, Inc., (Sparta), Hersteller von TrackWise(R) und der Marktführer in Unternehmensqualität und Compliance-Management-Software, kündigte heute an, dass Bayer HealthCare AG die TrackWise Software als Plattform für alle GCP und GLP Auditaktivitäten innerhalb des Pharmageschäftes von Bayer HealthCare ausgewählt hat. TrackWise ist ein webbasiertes Tracking-Software-Tool für die unternehmensweite elektronische Verwaltung, Protokollierung und Trendbestimmung in den Bereichen Qualität und regulatorische mehr...

Mehr zu dem Thema Aktuelle Wirtschaftsnews

Der meistgelesene Artikel zu dem Thema:

DBV löst Berechtigungsscheine von knapp 344 Mio. EUR ein

durchschnittliche Punktzahl: 0
Stimmen: 0

Bitte nehmen Sie sich einen Augenblick Zeit, diesen Artikel zu bewerten:

Exzellent
Sehr gut
gut
normal
schlecht